TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06750237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable surface and Isometrics
Description: will be treated by training the patients on unstable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable surface and isometrics
Description: and will be treated by training the patients on stable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week.
Study: NCT06751394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody (Toripalimab)
Description: PD-1 antibody: (Toripalimab): 240mg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine:1000mg/m² d1-14 q3w; Capecitabine:825mg/m² on the day of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 200 mg/m² q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 45-50Gy/25Fx or 30Gy/15Fx

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: The type of surgery will depend on the site of recurrence and the involvement of adjacent structures, which will be determined by the surgeons.
Study: NCT06189690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
Study: NCT05600660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Study: NCT05384964

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire completed by ICU nurses
Study: NCT06060184

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Next-Generation Sequencing (NGS)
Description: Sequencing of genomes (Long read NGS)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Next-Generation Sequencing (NGS)
Description: Sequencing of genomes (Long read NGS)
Study: NCT06477926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668 IR
Description: • Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668 ER
Description: • Oral Tablets
Study: NCT06555003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Control group will receive 2-4 cycles of systemic chemotherapy based on functional status of the patient, adverse event rate and treatment tolerance, tumor size and characteristics. Targeted therapy administration for each treatment group in based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status (e.g., administration of Pembrolizumab for patients with high rosatellite instability (MSI-H) or Bevacizumab for tumors harboring KRAS mutations). Due to the targeted nature of these therapies, they can not be administered to all participants of the trial, while It is not ethically justifiable to withhold targeted therapies from patients who are candidates for these treatments based on their tumor characteristics and deprive them of potentially life-extending options.
Study: NCT06750406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mind body exercises
Description: intervention might consist of a structured program of mind-body exercises designed specifically for pregnant women. This could involve a combination of yoga sessions, mindfulness meditation practices, deep breathing exercises, and progressive muscle relaxation techniques. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: relaxation exercises
Description: It involves relaxation exercises including deep breathing, relaxing postures etc. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for 8 weeks
Study: NCT06749665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polidacanol 3%
Description: Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polidacanol 3%
Description: Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: candida antigen
Description: delayed type of hypersensitivity reaction is induced toward the injected antigen and the wart virus as well. This can increase the ability of the immune system to recognize and eradicate the human papillomavirus on various parts of the body and eliminate the necessity of local treatment for each wart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: candida antigen
Description: delayed type of hypersensitivity reaction is induced toward the injected antigen and the wart virus as well. This can increase the ability of the immune system to recognize and eradicate the human papillomavirus on various parts of the body and eliminate the necessity of local treatment for each wart
Study: NCT06748209

Intervention type: DEVICE
Group type: OTHER
Intervention: Left prefrontal Transcranial Magnetic Stimulation (TMS)
Description: FDA cleared TMS

Intervention type: DEVICE
Group type: OTHER
Intervention: FDA cleared TMS for treating depression
Description: This is FDA approved TMS
Study: NCT06750783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuezhikang
Description: The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: The atorvastatin group takes atorvastatin 20mg once a day, orally after meals.
Study: NCT06750653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CeraVe Moisturizing Cream
Description: CeraVe is a formulation of Purified Water, Glycerin, Cetareth-20 and Cetearyl Alcohol, Caprylic/Capric Triglyceride, Behentrimonium Methosulfate and Cetearyl Alcohol, Cetyl Alcohol, Petrolatum, Dimethicone, Hyaluronic Acid, Ceramide 1, Ceramide 3, Ceramide 6-II, Cholesterol, Phytosphingosine, Potassium Phosphate, Dipotassium phosphate, Phenoxyethanol, Methylparaben, Propylparaben, Disodium EDTA, Sodium Lauroyl Lactylate, Carbomer, Xanthan Gum, manufactured by L'Oréal, for topical skin use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CeraVe Moisturizing Cream
Description: CeraVe is a formulation of Purified Water, Glycerin, Cetareth-20 and Cetearyl Alcohol, Caprylic/Capric Triglyceride, Behentrimonium Methosulfate and Cetearyl Alcohol, Cetyl Alcohol, Petrolatum, Dimethicone, Hyaluronic Acid, Ceramide 1, Ceramide 3, Ceramide 6-II, Cholesterol, Phytosphingosine, Potassium Phosphate, Dipotassium phosphate, Phenoxyethanol, Methylparaben, Propylparaben, Disodium EDTA, Sodium Lauroyl Lactylate, Carbomer, Xanthan Gum, manufactured by L'Oréal, for topical skin use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline
Description: Vaseline is a formulation of active ingredient white petrolatum, USP (100%), manufactured by Unilever, for topical skin use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline
Description: Vaseline is a formulation of active ingredient white petrolatum, USP (100%), manufactured by Unilever, for topical skin use.
Study: NCT06749158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spontaneous bone regeneration
Description: stage 1 surgery:~1. after administration of Local anesthesia (articaine hydrochloride 68 mg/1.7 ml + adrenaline 0.017 mg/1.7 ml injectable solution), sulcular incision will be done , extending two teeth beyond the area of interest followed by two oblique incisions on either side of the flap~2. after flap elevation, enucleation of the cystic lesion and extraction of the non-restorable teeth related to the lesion will be done.~3. titanium mesh will be tailored with 3 mm overlap at the edges to cover the bone window completely and fixed to the bone using mono-cortical titanium screws.~This will be followed by:~* proper decompression of soft tissue to achieve tension-reduced suture.~* Primary closure will be performed using 4-0 vicryl sutures.~* Sutures will be removed one week postoperatively. stage 2 surgery(after 6 months):~  1. titanium mesh and screws will be removed.~ 2. core biopsy will be obtained for histological assessment~ 3. implant/s placement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone regeneration
Description: stage 1 surgery after cyst enucleation and extraction of the non-restorable teeth related to the lesion, The intra-bony defect will be filled with Deproteinized Bovine Bone.~* Titanium mesh will be tailored with 3mm overlap at the edges to cover the bone window completely and fixed to the bone using mono-cortical titanium screws. This will be followed by:~* proper decompression of soft tissue will be applied to achieve tension-reduced suture.~* Primary closure will be performed using 4-0 vicryl sutures.~* Sutures will be removed one week postoperatively. stage 2 surgery(6 months later) :~  1. titanium mesh will be removed.~ 2. core biopsy will be obtained for histological assessment.~ 3. implant/s placement.
Study: NCT06749093

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered Air (FA)
Description: Exposure to HEPA filtered air, as a control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wood Smoke (WS)
Description: Wood smoke (WS) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel Exhaust (DE)
Description: Diesel exhaust (DE) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel Exhaust and Wood Smoke (DEWS)
Description: Combined diesel exhaust and wood smoke standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Study: NCT06748300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web- based education
Description: breastfeeding education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web- based education
Description: breastfeeding education
Study: NCT06750276

Intervention type: DRUG
Group type: OTHER
Intervention: AZD2389
Description: Doses of AZD2389 or placebo will be administered orally.

Intervention type: DRUG
Group type: OTHER
Intervention: AZD2389
Description: Doses of AZD2389 or placebo will be administered orally.
Study: NCT06749691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan and Apatinib
Description: Liposomal Irinotecan in Combination With Apatinib
Study: NCT06748248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: suspension Therapy
Description: suspension therapy for individuals with Down syndrome is an approach that focuses on improving mobility and balance through different activities that will be conducted through universal exercise unit. This method involves organizing individuals with Down syndrome into two groups. Group A will perform Suspension Therapy in addition to routine physical therapy. These routine exercises will consist of stretching exercises (arm raises, chest stretch, leg swings, hamstring stretch, cat-cow poses, starfish stretch), strength and endurance training (like stepping, carrying light weights) and balance training (playing hopscotch and kicking a ball). The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. Suspension Therapy will consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. Repeated corrective movements will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Treatment
Description: Group B will perform routine physical therapy (RPT) alone. These routine exercises will consist of stretching exercises (particularly upper and lower body stretches and full body stretches). Stretches will be gentle and avoid bouncing. Hold for each stretch will be 15-30 seconds. Balance and coordination exercises (Walking on balance beams, obstacle courses) will be performed as RPT. The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. These exercises will be carried out 5 days in a week for one hour daily.~Data will be assessed by assessor at baseline and at the end of 5th session of treatment (Pre and post).
Study: NCT06477926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668 ER
Description: • Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668 ER
Description: • Oral Tablets
Study: NCT06277557

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality
Description: Virtual reality learning platform as intervention in this study
Study: NCT05720208

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SCiP
Description: Noninvasive Spinal Cord Neuromodulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCiP
Description: Noninvasive Spinal Cord Neuromodulator
Study: NCT06477926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668 ER
Description: • Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668 ER
Description: • Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-668 ER
Description: • Oral Tablets
Study: NCT06526949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: To provide patients with a suitable environment during the intervention, screens will be lowered and earplugs will be used to ensure a quiet environment. The reiki practitioner will place his/her hands lightly on or above the patient's head and eyes, upper body from the neck to the pelvic area, arms and legs (standard reiki hand positions) for the duration of the therapy (30 minutes total duration).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: (Sham Reiki)
Description: In the sham (Sham Reiki) group, sham practitioners (not involved in the research) who have no experience in energy work will prepare a screen and headphones for the patients as in the intervention group. Then, they will place their hands gently on or above the patient's head and eyes, upper body from the neck to the pelvic region, arms and legs (standard reiki hand positions) for 30 minutes every other day for 2 days in a row or 2 times (Day 1 and Day 3) like the practitioner in the intervention group. Patient data will be recorded on forms before and after placebo administration as in the intervention group.
Study: NCT04966832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW10508
Description: XW10508 capsules or tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules or tablets
Study: NCT06628817

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: The Intensive Care Bundle with Mortality Reduction
Description: a continuous automated medical quality monitoring and feedback system on the online platform, self-feedback and teamwork based on video conferencing, multidisciplinary online education, offline on-site supervision, and standardized intervention in the behavior of medical actors in the process of stroke treatment.
Study: NCT06630884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid VI Polysaccharide Vaccine Injectable Solution
Description: Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo (0.5mL injection)
Description: The placebo injection will consist of 0.5mL of saline.
Study: NCT06628791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BK329
Description: Lactococcus lactics. subsp. lactis CAB701(KCCM13360P) 400 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400 mg/day for 12 weeks
Study: NCT06629649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.
Description: Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.
Study: NCT06630975

Intervention type: DEVICE
Group type: OTHER
Intervention: Hemiepiphysiodesis
Description: 8 plate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemiepiphysiodesis
Description: 8 plate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiepiphysiodesis
Description: 8 plate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiepiphysiodesis
Description: 8 plate

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Eight-Plates first described by Stevens are simple to use
Description: fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eight-Plates first described by Stevens are simple to use
Description: fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eight-Plates first described by Stevens are simple to use
Description: fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eight-Plates first described by Stevens are simple to use
Description: fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded

Intervention type: DEVICE
Group type: OTHER
Intervention: Hemiepiphysiodesis by eight Plate
Description: Extraperiosteal eight plate insertion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemiepiphysiodesis by eight Plate
Description: Extraperiosteal eight plate insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiepiphysiodesis by eight Plate
Description: Extraperiosteal eight plate insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiepiphysiodesis by eight Plate
Description: Extraperiosteal eight plate insertion
Study: NCT05954507

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MRI
Description: PET/MRI is a new-generation hybrid camera capable of simultaneously performing FDG positron emission tomography and gadolinium-injected MRI. PET/MRI could be a relevant prognostic marker of progression, and could significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis.
Study: NCT06067178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Dialogue Intervention
Description: 1. Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose.~2. Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opportunistic Screening
Description: 1. Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment.~2. Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening.